Shuqiao Cheng

5PUBLICATIONS
11CO-AUTHORS
Haematological tumoursMolecular targetsPharmacogenomicsRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Apr 30, 2025
Tremelimumab plus durvalumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the US payer perspective.

Shuqiao Cheng, Bin Li, Lanhua Tang

|Feb 22, 2025
Risk of acute renal failure associated with combined use of SGLT2 inhibitors and potentially nephrotoxic drugs: an epidemiological surveillance study based on the FDA adverse event reporting system (FAERS).

Ting Yu, Jian Xiao, Mengyao Li

|Feb 11, 2025
Smart Pharmaceutical Monitoring System With Personalized Medication Schedules and Self-Management Programs for Patients With Diabetes: Development and Evaluation Study.

Jian Xiao, Mengyao Li, Ruwen Cai

|Jul 15, 2024
Construction and application of medication reminder system: intelligent generation of universal medication schedule.

Hangxing Huang, Lu Zhang, Yongyu Yang

|Jul 04, 2024
Analysis of hemorrhagic drug-drug interactions between P-gp inhibitors and direct oral anticoagulants from the FDA Adverse Event Reporting System.

Mengyao Li, Jian Xiao, Ting Yu

Pageof 1

Frequent Collaborators

5 joint publications

Jian Xiao

3 joint publications

Ting Yu

3 joint publications

Mengyao Li

3 joint publications

Ruwen Cai